Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 8/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GRK5 | P34947 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12078774 | 0.84 | NUDT1 (0.66) | NUDT1FYNEGLN2JAK1KDM4E | |
| SCHEMBL2250300 | 0.79 | NUDT1 (0.73) | NUDT1EGLN2JAK1KDM4EALDH1A1 | |
| SCHEMBL2634433 | 0.79 | PIK3CG (0.54) | NUDT1JAK1 | |
| SCHEMBL15289888 | 0.76 | JAK2 (0.43) | NUDT1FYNJAK1KDM4EGAA | |
| SCHEMBL15268822 | 0.76 | EGLN2 (0.45) | NUDT1EGLN2JAK1KDM4EALDH1A1 | |
| SCHEMBL32664865 | 0.74 | NUDT1 (0.39) | NUDT1EGLN2JAK1KDM4EALDH1A1 | |
| SCHEMBL15269263 | 0.73 | NUDT1 (0.55) | NUDT1FYNEGLN2JAK1KDM4E | |
| SCHEMBL15268998 | 0.73 | FYN (0.46) | NUDT1FYNMKNK1GRK5 | |
| SCHEMBL15268957 | 0.73 | CDK8 (0.41) | NUDT1EGLN2JAK1 | |
| SCHEMBL15269429 | 0.73 | NPC1 (0.49) | NUDT1MKNK1EGLN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536710-B1 | PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2822948-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2822948-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-20150051202-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051202-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051202-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-19 | — | — | US | disclosed |
| EP-2822948-A1 | TRIAZOLOPYRAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013131609-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013131609-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-09-12 | — | — | WO | disclosed |
| US-8486967-B2 | Heteroaryl substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2536710-A2 | PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| EP-2531503-A1 | GAMMA SECRETASE MODULATERS | F. Hoffmann-La Roche AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011101304-A2 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
| WO-2011092272-A1 | GAMMA SECRETASE MODULATERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | BACE1, APH1A, APH1B | NUDT1 1834/4885FYN 906/4885MKNK1 4208/4885 |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | NUDT1 1439/4885FYN 824/4885MKNK1 4561/4885 |
| US-20150051202-A1 | TRIAZOLOPYRAZINE DERIVATIVES | EIF2AK4, GCN1, GTF2I | NUDT1 1317/4885FYN 4172/4885MKNK1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.